Evidence map›Paper›PMID 29017536›Full record

ArticleRetrovirology2017

A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies.

Donglai Liu, Chu Wang, Bhavna Hora, Tao Zuo, Nilu Goonetilleke, Michael K P Liu, Mark Berrong, Guido Ferrari, Andrew J McMichael, Tanmoy Bhattacharya and 2 more

Abstract read
In one paragraph

Article in Retrovirology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Donglai LiuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.
Chu WangNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.
Bhavna HoraDepartment of Medicine, Duke Human Vaccine Institute, Duke University Medical Center, 303 Research Dr., 244 Sands Building, DUMC 102359, Durham, NC, 27710, USA.
Tao ZuoNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.
Nilu GoonetillekeDepartment of Microbiology, Immunology and Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Michael K P LiuWeatherall Institute of Molecular Medicine, University of Oxford, Oxford, England, UK.
Mark BerrongDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Guido FerrariDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Andrew J McMichaelWeatherall Institute of Molecular Medicine, University of Oxford, Oxford, England, UK.
Tanmoy BhattacharyaTheoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Alan S PerelsonTheoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Feng GaoNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China. fgao@duke.edu.ORCID http://orcid.org/0000-0001-8903-0203

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI LETVIN, NORMAN L · 2006 to 2011
$290.5M
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F · 2005 to 2005
$14.9M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
Immune System Modeling/HIVR37AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 2002 to 2011
$2.4M
Medical Research Council MR/K012037/1NIAID NIH HHS R01 AI028433NIAID NIH HHS R37 AI028433NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854NIAID NIH HHS UM1 AI100645NIH HHS R01 OD011095
6 · The paper itself

Abstract

backgroundMutations rapidly accumulate in the HIV-1 genome after infection. Some of those mutations are selected by host immune responses and often cause viral fitness losses. This study is to investigate whether strongly selected mutations that are not associated with immune responses result in fitness losses.

resultsStrongly selected mutations were identified by analyzing 5'-half HIV-1 genome (gag/pol) sequences from longitudinal samples of subject CH0131. The K43R mutation in the gag gene was first detected at day 91 post screening and was fixed in the viral population at day 273 while the synonymous N323tc mutation was first detected at day 177 and fixed at day 670. No conventional or cryptic T cell responses were detected against either mutation sites by ELISpot analysis. However, when fitness costs of both mutations were measured by introducing each mutation into their cognate transmitted/founder (T/F) viral genome, the K43R mutation caused a significant fitness loss while the N323tc mutation had little impact on viral fitness.

conclusionsThe rapid fixation, the lack of detectable immune responses and the significant fitness cost of the K43R mutation suggests that it was strongly selected by host factors other than T cell responses and neutralizing antibodies.

Indexed as

Antibodies, NeutralizingCD8-Positive T-LymphocytesCell Culture TechniquesEnzyme-Linked Immunospot AssayEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency VirusGenetic FitnessGenome, ViralHIV-1HIV InfectionsHumansImmune EvasionMutationSelection, GeneticVirus ReplicationAntibodies, NeutralizingEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency VirusCryptic T cell responseEscapeFitnessImmune responsesMutationSelection

Identifiers

PMID29017536
PMCPMC5634943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.